Search Results for "Axiron"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Axiron. Results 1 to 5 of 5 total matches.
Testosterone Topical Solution (Axiron) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jul 11, 2011 (Issue 1368)
Testosterone Topical Solution (Axiron) for Hypogonadism ...
The Medical Letter recently reviewed a topical gel formulation
of testosterone (Fortesta) for treatment of
hypogonadism in men. A topical testosterone replacement
product for application to the axilla, Axiron (Lilly)
solution, has now become available for the same indication.
This site of application presumably minimizes
the risk of transferring the drug to a family member or
sexual partner.
A Long-Acting Depot Formulation of Testosterone (Aveed)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2014 (Issue 1439)
mg test.)
88 g MDP
(20.25 mg test.
in 1.25 g gel/act.)
Axiron (Lilly) 90 mL MDP 60 mg once/d ...
The FDA has approved testosterone undecanoate (Aveed –
Endo), an injectable depot formulation, for use in men
with hypogonadism who require testosterone replacement
therapy.
Safety of Testosterone Replacement Therapy
The Medical Letter on Drugs and Therapeutics • Mar 14, 2016 (Issue 1490)
489.00
(40.5 mg test.); 75 g MDP (20.25 mg test. in 1.25 g gel/act)
Axiron (Lilly) 90 mL MDP (30 mg ...
Three coordinated double-blind, placebo-controlled
clinical trials have evaluated the efficacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in a total of
790 men ≥65 years old with moderately low serum
testosterone concentrations and symptoms suggesting
hypoandrogenism. Sexual function improved
modestly, and there appeared to be marginal benefits
in some areas of physical function and vitality as well.
The trials were not designed to evaluate the safety of
testosterone replacement therapy.
Testosterone Nasal Gel (Natesto) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
mg test.); 75 g MDP (20.25 mg
test. in 1.25 g gel/act)
Axiron (Lilly) 90 mL MDP (30 mg test. in 1.5 ...
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first intranasal
testosterone to become available in the US. Like other
testosterone products, it is classified as a schedule
III controlled substance. The FDA recently cautioned
against using testosterone to treat low testosterone
levels solely due to aging because the benefits and
safety of such use have not been established, and there
is a possible increased risk of myocardial infarction...
Jatenzo - An Oral Testosterone for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
required weekly.
8. Administered as 2 pump actuations to each thigh.
9. For axillary application. Axiron ...
An oral formulation of testosterone undecanoate
(Jatenzo – Clarus) has been approved by the FDA for
treatment of adult men with conditions associated
with a deficiency of endogenous testosterone, such as
Klinefelter syndrome, orchiectomy, toxic damage from
chemotherapy or alcohol, or pituitary-hypothalamic
injury from tumors, trauma, or radiation. Jatenzo is
not approved for treatment of low testosterone levels
solely due to aging. It is the first oral testosterone
formulation to be approved in the US.